Beyond hereditary hemochromatosis: New insights into the relationship between iron overload and chronic liver diseases

2011 ◽  
Vol 43 (2) ◽  
pp. 89-95 ◽  
Author(s):  
Silvia Fargion ◽  
Luca Valenti ◽  
Anna Ludovica Fracanzani
Keyword(s):  
Iron Overload ◽  
Liver Diseases ◽  
Hereditary Hemochromatosis ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
The Relationship

scholarly journals Association between Albumin-Bilirubin Grade and Non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases

2019 ◽  
Vol 8 (9) ◽  
pp. 1485 ◽  
Author(s):  
Ryo Takata ◽  
Hiroki Nishikawa ◽  
Hirayuki Enomoto ◽  
Kazunori Yoh ◽  
Yoshinori Iwata ◽  
...  
Keyword(s):  
Respiratory Quotient ◽  
Liver Diseases ◽  
Multivariate Analyses ◽  
Independent Predictor ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Optimal Cutoff ◽  
Optimal Cutoff Point ◽  
Grade 3 ◽  
The Relationship

We sought to elucidate the relationship between albumin-bilirubin (ALBI) grade and non-protein respiratory quotient (npRQ) calculated by indirect calorimetry in chronic liver disease (CLD) patients (n = 601, median age = 63 years). Factors linked to npRQ < 0.85, which is reported to be an optimal cutoff point for the prognosis in liver cirrhosis (LC) patients, were also investigated using univariate and multivariate analyses. The median npRQ for all cases was 0.86. In total, 253 patients (42.1%) had npRQ < 0.85. The proportions of patients with npRQ < 0.85 in LC and non-LC patients were 51.9% (166/320) in LC patients and 31.0% (87/281) in non-LC patients (p < 0.0001). The median npRQ in ALBI grades 1, 2, and 3 for all cases were: 0.89, 0.85, and 0.82 (overall p < 0.0001). The proportions of patients with npRQ < 0.85 were 31.0% (71/229) in ALBI grade 1, 46.34% (152/328) in ALBI grade 2, and 68.18% (30/44) in ALBI grade 3 (overall p < 0.0001). In multivariate analyses of factors linked to npRQ < 0.85, ALBI grade 3 (p = 0.0095, hazard ratio = 3.242, ALBI grade 1 as a reference) was an independent predictor along with prothrombin time (p = 0.0139). In conclusion, ALBI grade can be a useful marker for npRQ in patients with CLDs.

PPARα Agonist Fenofibrate Attenuates Iron Induced Liver Injury in Mice by Modulating the Sirt3 and β-catenin Signaling

2021 ◽  
Author(s):  
Ashok Mandala ◽  
William J Chen ◽  
Austin Armstrong ◽  
Milan R Malhotra ◽  
Sanmathi Chavalmane ◽  
...  
Keyword(s):  
Liver Injury ◽  
Iron Overload ◽  
Liver Diseases ◽  
Critical Role ◽  
Chronic Liver ◽  
Iron Accumulation ◽  
Hepatic Iron ◽  
Chronic Liver Diseases ◽  
Pparα Agonist

Iron accumulation is frequently associated with chronic liver diseases. However, our knowledge on how iron contributes to the liver injury is limited. Aberrant Wnt/β-catenin signaling is a hallmark of several hepatic pathologies. We recently reported that peroxisome proliferator activated receptor alpha (PPARα) agonist, fenofibrate prevents iron induced oxidative stress and β-catenin signaling by chelating the iron. Sirtuin3 (Sirt3), a type of NAD+-dependent deacetylase that plays a critical role in metabolic regulation was found to prevent ischemia reperfusion injury by normalizing the Wnt/β-catenin pathway. In the present study, we explored if fenofibrate prevents iron induced liver injury by regulating the Sirt3 and β-catenin signaling. In-vitro and in-vivo iron treatment resulted in the downregulation of PPARα, Sirt3, active β-catenin and its downstream target gene c-Myc in the mouse liver. Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active β-catenin expression and prevented the iron induced upregulation of αSMA and TGFβ expression. Intrinsically, PPARα KO mice showed significant downregulation of hepatic Sirt3 levels. In addition, treatment of iron overload mice with PPARα agonist fenofibrate reduced hepatic iron accumulation and prevented iron induced downregulation of liver Sirt3 and active β-catenin, mitigating the progression of fibrosis. Thus, our results establish a novel link between hepatic iron and PPARα, Sirt3 and β-catenin signaling. Further exploration on the mechanisms by which fenofibrate ameliorates iron induced liver injury likely has significant therapeutic impact on iron associated chronic liver diseases.

scholarly journals Iron Overload andHFEGene Mutations in Czech Patients with Chronic Liver Diseases

2012 ◽  
Vol 32 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Marketa Dostalikova-Cimburova ◽  
Karolina Kratka ◽  
Jaroslav Stransky ◽  
Ivana Putova ◽  
Blanka Cieslarova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Iron Overload ◽  
Alcoholic Liver Disease ◽  
Liver Diseases ◽  
Gene Mutations ◽  
Chronic Liver ◽  
Chronic Liver Diseases

The aim of the study was to identify the prevalence ofHFEgene mutations in Czech patients with chronic liver diseases and the influence of the mutations on iron status. The presence ofHFEgene mutations (C282Y, H63D, and S65C) analyzed by the PCR-RFLP method, presence of cirrhosis, and serum iron indices were compared among 454 patients with different chronic liver diseases (51 with chronic hepatitis B, 122 with chronic hepatitis C, 218 with alcoholic liver disease, and 63 patients with hemochromatosis). Chronic liver diseases patients other than hemochromatics did not have an increased frequency ofHFEgene mutations compared to controls. Although 33.3% of patients with hepatitis B, 43% of patients with hepatitis C, and 73.2% of patients with alcoholic liver disease had elevated transferrin saturation or serum ferritin levels, the presence ofHFEgene mutations was not significantly associated with iron overload in these patients. Additionally, patients with cirrhosis did not have frequencies ofHFEmutations different from those without cirrhosis. This study emphasizes the importance, not only of C282Y, but also of the H63D homozygous genetic constellation in Czech hemochromatosis patients. Our findings show that increased iron indices are common in chronic liver diseases butHFEmutations do not play an important role in the pathogenesis of chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease.

The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases

2006 ◽  
Vol 26 (2) ◽  
pp. 187-196 ◽  
Author(s):  
Marlyn J. Mayo ◽  
James M. Mosby ◽  
Rohan Jeyarajah ◽  
Burton Combes ◽  
Smina Khilnani ◽  
...  
Keyword(s):  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Immunoglobulin Production ◽  
The Relationship

scholarly journals Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies

2016 ◽  
Vol 89 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Olga Hilda Orasan ◽  
George Ciulei ◽  
Angela Cozma ◽  
Madalina Sava ◽  
Dan Lucian Dumitrascu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Diseases ◽  
Hereditary Hemochromatosis ◽  
Public Health Problem ◽  
Chronic Viral Hepatitis ◽  
Chronic Liver ◽  
Biliary Cirrhosis ◽  
Chronic Liver Diseases ◽  
Alcoholic Fatty Liver

Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis.Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic fatty liver disease, HIV-HCV coinfection, alcoholic liver disease, primary biliary cirrhosis, biliary atresia, hereditary hemochromatosis and cystic fibrosis. 

Iron overload in chronic liver diseases and clinical usefulness of therapeutic phlebotomy: Our experience

2006 ◽  
Vol 38 ◽  
pp. S185
Author(s):  
C. Farinato ◽  
M. Di Pierro ◽  
G. Amalfi ◽  
G. Caravelli ◽  
V. D'Angelo ◽  
...  
Keyword(s):  
Iron Overload ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Clinical Usefulness ◽  
Chronic Liver Diseases

scholarly journals Chronic Kidney Disease – Chronic Liver Disease. An Immunologic Cross-talk

2015 ◽  
Vol 53 (1) ◽  
pp. 3-12
Author(s):  
Gh. Gluhovschi ◽  
Ligia Petrica ◽  
I. Sporea ◽  
Manuela Curescu ◽  
Silvia Velciov ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Immune System ◽  
Liver Disease ◽  
Kidney Disease ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Immune Mechanisms ◽  
The Relationship

Abstract The relationship between the kidney and other organs is notable. The bestknown is the relation with the cardiovascular system. Relationships with other organs are less studied, although their involvement sometimes dominates the clinical picture and the outcome of disease. The paper analyzes the kidney-liver relationship, namely chronic kidney disease and chronic liver disease from an immune viewpoint. The immune system operates as a unitary whole. There is an interdependence between the immune system of the liver, considered a lymphoid organ, and the kidney, whose participation in immune processes is well-known. The most important chronic liver diseases are viral hepatitis B and C. Infection with these viruses can lead to renal involvement, producing mainly glomerular disease. At the same time, secondary glomerulonephritis can cause an unfavorable outcome of the primary disease. The relationship between chronic liver disease and chronic kidney disease during chronic B and C hepatitis occurs via circulating immune complexes or complexes formed in situ. Cell-mediated immunity is also involved. The antiviral treatment of B and C hepatitis is also aimed at secondary glomerular disease. The participation of immune mechanisms raises the question of administering immunomodulating medication, a type of medication that influences viral replication - this is why it is associated with antiviral medication. Other two chronic liver diseases, namely liver cirrhosis, in which the main mechanism is a toxic one, and non-alcoholic steatohepatitis can produce via immune mechanisms glomerular involvement. In its turn, chronic kidney disease in advanced stages causes lipid metabolism disturbances with hypertriglyceridemia, which can influence fatty loading of the liver in the above-mentioned liver diseases. One can speak about a cross-talk between the liver and the kidney, in which immune mechanisms play an important role.

Sign in / Sign up

Export Citation Format

Share Document